PUBLISHER: Allied Market Research | PRODUCT CODE: 1414810
PUBLISHER: Allied Market Research | PRODUCT CODE: 1414810
The hematology diagnostic market is likely to experience a significant growth rate of 4.4% from 2023-2032 owing to increasing market demand from medical device & supplies sector - Allied Market Research
Blood is composed of multiple components, including plasma (which makes up approximately 55% of the volume) and red, white, and platelet cells (which together make up approximately 45% of the volume). About 45% of entire blood is composed of red blood cells, usually referred to as erythrocytes or RBCs, transport oxygen from the lungs to the body's tissue. White blood cells, also produced in the bone marrow and referred to as leukocytes or WBCs, aid in the fight against infection. They comprise less than 1% of whole blood, together with platelets. Diagnosis of diseases related to these cells such as hematologic malignancies, coagulopathy, anemia, and hemoglobinopathy are considered under hematology diagnostics. Various instruments and consumables are used in the process of hematology diagnosis for blood collections and screening.
The most commonly performed hematology test is the complete blood count, or CBC. This test is frequently performed as part of a routine examination, and can identify infections, immune system diseases, blood malignancies, anemia, and clotting issues. CBC hematology test includes platelet count, hematocrit red blood cell volume (HCT), hemoglobin concentration (HB), differential white blood count, red blood cell indices and red blood cell count (RBC).
Major factors driving the growth of hematology diagnostics market include rising incidences of blood disorders, rising prevalence of chronic diseases requiring regular hematological testing, and rising awareness among population regarding routine physical checkups. The need for hematology diagnostics is growing as the incidences of blood disorders increase. It is necessary to carry out routine testing and monitoring on patients with suspected or confirmed blood disorders in order to make a diagnosis, assess the severity of the problem, and monitor its course. This is driving the market for hematology diagnostics.
In addition, effective treatment and management of blood diseases depend on early diagnosis and detection of the condition. The significance of early diagnosis has become more widely recognized because of the increased incidences of these illnesses. Hematology test recommendations and execution are mostly recommended by the healthcare professionals, which is fueling the market's expansion.
The market for hematology diagnostics is segmented on the basis of product type, test type, end user, and region. On the basis of product type, the market is segmented into hematology instrument and hematology consumables. The hematology instrument segment is further segmented into hematology analyzers, flow cytometers and others. The hematology analyzers segment is further segmented into fully automated hematology analyzers and semi-automated hematology analyzers, whereas flow cytometry segment is further segmented into cell-based flow cytometry and bead-based flow cytometry. On the basis of test type, the market is segmented into complete blood count (CBC), platelet function test, hemoglobin test and others. Based on end user, the market is segmented into Hospitals & clinics, diagnostic laboratories, and others.
By region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA. Major players profiled in this report are Cardinal Health Inc., Danaher Corporation, Siemens AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Abbott Laboratories, EKF Diagnostics Holdings plc, Nihon Kohden Corporation, and Erba Group.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
Type
Type